JAK2 and colorectal carcinoma: Previously, our laboratory has demonstrated that anlotinib combined with DDP significantly inhibited the proliferation of colorectal cancer (CRC) cells by antagonizing the VEGFR/Janus kinase 2 (JAK2)/signal transducer and activating transcription-3 (STAT3) (Jia et al., 2021).